Lv713
3700 积分 2024-02-04 加入
Selective Elimination of Breast Surgery for Invasive Breast Cancer
17天前
已完结
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
21天前
已完结
92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8
21天前
已完结
Abstract OT-15-01: A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR+) breast cancer
21天前
已关闭
Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer
21天前
已完结
Abstract P4-07-16: B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers
21天前
已关闭
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
21天前
已完结
免疫检查点抑制剂在激素受体阳性乳腺癌新辅助治疗中的研究进展
21天前
已完结
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
23天前
已完结
HSR25-159: Real-World Effectiveness of First-Line Osimertinib for Patients in the US With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer Who Were Eligible for Medicare
27天前
已关闭
皖公网安备34019202002308
